In previous studies, PGC1α was also considered an important therapeutic target for type 2 diabetes and obesity through regulating mitochondrial biogenesis and interacting with transcription factors such as estrogen-related receptors, liver X receptors, and hepatic nuclear factor 4α to coordinate the expression of mitochondrial genes and indirectly promote the transport and utilization of fatty acids (FAs), thereby regulating glucolipid metabolism [16,17,18]. This evidence concerns the gene PPARGC1A and obesity due to melanocortin 4 receptor deficiency.